Teva receives tentative OK for generic osteoporosis drug
However, final approval is subject to the resolution of pending patent litigation after Procter & Gamble sued Teva last year over patent infringement of the drug. If Teva
China-based Biocytogen Pharmaceuticals has entered a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human VHH antibody molecule.